0.80
+0.0255(+3.31%)
Currency In USD
Address
One Research Court
Rockville, MD 20850
United States of America
Phone
240 403 4212
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
8
First IPO Date
August 31, 2022
| Name | Title | Pay | Year Born |
| Dr. Anatoly Dritschilo M.D. | Co-Founder, Chief Executive Officer & Chairman of the Board | 399,175 | 1944 |
| Dr. Tyvin A. Rich M.D. | Chief Clinical Officer & Chief Medical Officer | 263,226 | 1948 |
| Mr. Peter Dale Dritschilo M.B.A., M.D. | President & Chief Operating Officer | 314,012 | 1969 |
| Dr. Milton Brown CSC, M.D., Ph.D. | Co-Founder & Director | 0 | 1965 |
| Mr. Gene Jung Esq. | General Counsel | 0 | N/A |
| Dr. Mira Jung Ph.D. | Co-Founder & Chief Scientific Officer for Biology | 0 | 1949 |
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.